U.S.S.N. 10/099,830 Filed: March 13, 2003

AMENDMENT AND RESPONSE TO OFFICE ACTION

Amendment

In the Claims

Claims 1-33 (Canceled).

34. (previously presented) A therapeutic system comprising a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 and a compound of formula I

$$\mathbb{R}^2$$
 \mathbb{R}^3
 \mathbb{R}^3
 \mathbb{R}^3

wherein R1 is selected from the group consisting of substituted alkyl, including substitution by CONH₂, OH, halogen, CN, and COOH; aryl; substituted aryl; CONR₂R₅, where R₂ and R₃ are independently H, alkyl, or substituted alkyl, and R² and R³ are independently H, alkyl, or substituted alkyl and R⁴ is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH₂, or OH, wherein the compound can pass reducing equivalents to NQO2, in a form for administration to a patient in need thereof, wherein the prodrug is CB 1954.

Claims 35-40 (Canceled)

41. (Previously Presented) The system of claim 34, wherein the compound is 1-(carboxamidomethyl)-dihydronicotinamide.

45061172

2

ERD 100 CON 078230/31 U.S.S.N. 10/099,830
Filed: March 13, 2003
AMENDMENT AND RESPONSE TO OFFICE ACTION

42. (previously presented) The system of claim 34, wherein the compound has formula

wherein R is a substituted alkyl, comprising one or more groups selected from the group consisting of CONH₂, OH, halogen, CN, and COOH.

- 43. (Previously Presented) The system of claim 34, wherein the alkyl group is a C1 to C6 alkyl.
- 44. (previously presented) The system of claim 42, wherein R is selected from the group consisting of -CH₂CONH₂, -CH₂CH₂CH₂COH₂, -CH₂CH₂CH₂OH, and -CH₂CH₂COOH.

45-47. (Canceled)

48. (new) The therapeutic system of claim 34 wherein the system is effective at killing tumor cells in the treatment of cancer.

45061172

II

3

ERD 100 CON 078230/31